JP2018514510A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514510A5 JP2018514510A5 JP2017549388A JP2017549388A JP2018514510A5 JP 2018514510 A5 JP2018514510 A5 JP 2018514510A5 JP 2017549388 A JP2017549388 A JP 2017549388A JP 2017549388 A JP2017549388 A JP 2017549388A JP 2018514510 A5 JP2018514510 A5 JP 2018514510A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- subject
- pharmaceutical composition
- use according
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 206010019860 Hereditary angioedema Diseases 0.000 claims 17
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 206010010904 Convulsion Diseases 0.000 claims 3
- 102000003827 Plasma Kallikrein Human genes 0.000 claims 3
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 238000012423 maintenance Methods 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000001488 sodium phosphate Substances 0.000 claims 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 2
- 102000010631 Kininogens Human genes 0.000 claims 1
- 108010077861 Kininogens Proteins 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021204200A JP7309836B2 (ja) | 2015-03-30 | 2021-12-16 | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 |
| JP2023110592A JP7826251B2 (ja) | 2015-03-30 | 2023-07-05 | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 |
| JP2026028435A JP2026094252A (ja) | 2015-03-30 | 2026-02-25 | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140277P | 2015-03-30 | 2015-03-30 | |
| US201562140289P | 2015-03-30 | 2015-03-30 | |
| US62/140,277 | 2015-03-30 | ||
| US62/140,289 | 2015-03-30 | ||
| US201562214293P | 2015-09-04 | 2015-09-04 | |
| US62/214,293 | 2015-09-04 | ||
| PCT/US2016/024921 WO2016160926A1 (en) | 2015-03-30 | 2016-03-30 | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021204200A Division JP7309836B2 (ja) | 2015-03-30 | 2021-12-16 | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018514510A JP2018514510A (ja) | 2018-06-07 |
| JP2018514510A5 true JP2018514510A5 (enExample) | 2019-05-09 |
| JP7008920B2 JP7008920B2 (ja) | 2022-01-25 |
Family
ID=57005262
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549388A Active JP7008920B2 (ja) | 2015-03-30 | 2016-03-30 | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 |
| JP2021204200A Active JP7309836B2 (ja) | 2015-03-30 | 2021-12-16 | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 |
| JP2023110592A Active JP7826251B2 (ja) | 2015-03-30 | 2023-07-05 | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 |
| JP2026028435A Pending JP2026094252A (ja) | 2015-03-30 | 2026-02-25 | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021204200A Active JP7309836B2 (ja) | 2015-03-30 | 2021-12-16 | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 |
| JP2023110592A Active JP7826251B2 (ja) | 2015-03-30 | 2023-07-05 | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 |
| JP2026028435A Pending JP2026094252A (ja) | 2015-03-30 | 2026-02-25 | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180298110A1 (enExample) |
| EP (2) | EP3286226A4 (enExample) |
| JP (4) | JP7008920B2 (enExample) |
| KR (3) | KR102607829B1 (enExample) |
| CN (1) | CN107614532A (enExample) |
| AU (3) | AU2016243160B2 (enExample) |
| BR (1) | BR112017020864A2 (enExample) |
| CA (2) | CA3290174A1 (enExample) |
| CO (1) | CO2017009404A2 (enExample) |
| EA (1) | EA201792161A1 (enExample) |
| HK (1) | HK1250995A1 (enExample) |
| IL (2) | IL254292B2 (enExample) |
| MX (2) | MX2017012423A (enExample) |
| WO (1) | WO2016160926A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2905545T3 (es) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| KR102011156B1 (ko) | 2011-01-06 | 2019-08-16 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
| JP2016513682A (ja) | 2013-03-15 | 2016-05-16 | ダイアックス コーポレーション | 抗血漿カリクレイン抗体 |
| ES3065185T3 (en) | 2014-01-21 | 2026-05-04 | Takeda Pharmaceuticals Co | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
| IL247942B (en) | 2014-03-27 | 2022-09-01 | Dyax Corp | Compositions and methods for drops in macular edema as a result of diabetes |
| US11286307B2 (en) * | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| IL314752A (en) * | 2016-09-16 | 2024-10-01 | Takeda Pharmaceuticals Co | Metabolite biomarkers for diseases associated with the contact activation system |
| EP4494698A3 (en) * | 2017-08-04 | 2025-04-23 | Takeda Pharmaceutical Company Limited | Inhibitors of plasma kallikrein and uses thereof |
| WO2019166572A1 (en) * | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
| EP3758702A4 (en) * | 2018-02-28 | 2021-11-10 | Attune Pharmaceuticals, Inc. | TREATMENT OF HEREDITARY ANGIOEDEMA |
| EP3843840A1 (en) * | 2018-08-30 | 2021-07-07 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| AU2020392243A1 (en) | 2019-11-28 | 2022-06-16 | Regenxbio Inc. | Microdystrophin gene therapy constructs and uses thereof |
| AU2021209045A1 (en) | 2020-01-13 | 2022-07-28 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| JP2023517611A (ja) * | 2020-03-10 | 2023-04-26 | ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー | Ｉｌ－６／ｉｌ－６ｒ抗体の組成物及びその使用方法 |
| CN114166924B (zh) * | 2021-12-03 | 2024-11-22 | 中国医学科学院北京协和医院 | 尿液蛋白标志物在诊断遗传性血管水肿中的用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| CA2180950C (en) | 1994-01-11 | 2005-03-29 | William Markland | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| PT2298278E (pt) | 2002-06-07 | 2016-02-25 | Dyax Corp | Prevenção e redução da perda de sangue e resposta inflamatória |
| US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| ES2905545T3 (es) * | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| KR102011156B1 (ko) * | 2011-01-06 | 2019-08-16 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
| UY34054A (es) * | 2011-05-02 | 2012-11-30 | Millennium Pharm Inc | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| EP4234583A3 (en) * | 2013-01-20 | 2024-01-24 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
| JP2016513682A (ja) * | 2013-03-15 | 2016-05-16 | ダイアックス コーポレーション | 抗血漿カリクレイン抗体 |
| KR20140119396A (ko) * | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| CN105873951A (zh) | 2013-10-21 | 2016-08-17 | 戴埃克斯有限公司 | 用于确定血浆激肽释放酶系统生物标记的试验 |
| ES3065185T3 (en) | 2014-01-21 | 2026-05-04 | Takeda Pharmaceuticals Co | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
-
2016
- 2016-03-30 CA CA3290174A patent/CA3290174A1/en active Pending
- 2016-03-30 BR BR112017020864-4A patent/BR112017020864A2/en not_active Application Discontinuation
- 2016-03-30 US US15/562,671 patent/US20180298110A1/en not_active Abandoned
- 2016-03-30 EP EP16774069.5A patent/EP3286226A4/en not_active Withdrawn
- 2016-03-30 KR KR1020177031279A patent/KR102607829B1/ko active Active
- 2016-03-30 HK HK18110329.1A patent/HK1250995A1/zh unknown
- 2016-03-30 IL IL254292A patent/IL254292B2/en unknown
- 2016-03-30 JP JP2017549388A patent/JP7008920B2/ja active Active
- 2016-03-30 KR KR1020257012913A patent/KR20250057946A/ko active Pending
- 2016-03-30 CN CN201680018200.7A patent/CN107614532A/zh active Pending
- 2016-03-30 CA CA2979713A patent/CA2979713C/en active Active
- 2016-03-30 EA EA201792161A patent/EA201792161A1/ru unknown
- 2016-03-30 IL IL305207A patent/IL305207A/en unknown
- 2016-03-30 KR KR1020237040648A patent/KR102799778B1/ko active Active
- 2016-03-30 EP EP21167802.4A patent/EP3916020A1/en active Pending
- 2016-03-30 WO PCT/US2016/024921 patent/WO2016160926A1/en not_active Ceased
- 2016-03-30 MX MX2017012423A patent/MX2017012423A/es unknown
- 2016-03-30 AU AU2016243160A patent/AU2016243160B2/en active Active
-
2017
- 2017-09-15 CO CONC2017/0009404A patent/CO2017009404A2/es unknown
- 2017-09-27 MX MX2023010206A patent/MX2023010206A/es unknown
-
2021
- 2021-10-13 US US17/500,214 patent/US20220169749A1/en active Pending
- 2021-12-16 JP JP2021204200A patent/JP7309836B2/ja active Active
-
2022
- 2022-05-12 AU AU2022203180A patent/AU2022203180B2/en active Active
-
2023
- 2023-07-05 JP JP2023110592A patent/JP7826251B2/ja active Active
-
2025
- 2025-11-21 AU AU2025271115A patent/AU2025271115A1/en active Pending
-
2026
- 2026-02-25 JP JP2026028435A patent/JP2026094252A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7194022B2 (ja) | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 | |
| JP2020002171A5 (enExample) | ||
| WO2019096194A1 (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2021535161A5 (enExample) | ||
| JP2019501886A5 (enExample) | ||
| WO2018068691A1 (zh) | 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途 | |
| JP2019514974A5 (enExample) | ||
| JP2020521797A5 (enExample) | ||
| JP2020535149A5 (enExample) | ||
| JP2023527542A5 (enExample) | ||
| Takeuchi et al. | OP0040 adding tocilizumab or switching to tocilizumab monotherapy in RA patients with inadequate response to methotrexate: 24-week results from a randomized controlled study (Surprise Study) | |
| Jung et al. | Mycophenolic acid trough concentration and dose are associated with hematologic abnormalities but not rejection in kidney transplant recipients | |
| CA3073555A1 (en) | [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy | |
| US20230038138A1 (en) | Combination therapy for treating cancer | |
| JP2023510854A5 (enExample) | ||
| Bernstein et al. | Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks | |
| JP2022530599A5 (enExample) | ||
| Fenier et al. | Enalapril improved renal function and proteinuria in chronic glomerulopathies | |
| Miller et al. | Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease—the DIVINE study | |
| JP2024174997A (ja) | Ｃｄ４７阻害物質、免疫チェックポイント阻害物質および標準療法の併用によるがん治療法 | |
| ZAREEIFAR et al. | Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia | |
| Yoshida et al. | Dexamethasone as a means not only for controlling vascular pain caused by the administration of oxaliplatin via the peripheral vein but also for controlling oxaliplatin-induced hypersensitivity reactions. | |
| JP2022520572A (ja) | 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置 | |
| RU2019108441A (ru) | Режим дозирования | |
| WO2019129168A1 (zh) | Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 |